Nucleic acid removal is an essential step in biologics production workflows. Our MaxNuclease™ enzyme is a non-specific endonuclease from Serratia...

On December 19, 2024, Omeros announced that its pivotal Phase 3 clinical trial of the MASP2 antibody Narsoplimab (OMS721) in...

Background The production of high-quality mRNA is critical for a wide range of applications, including gene therapy, vaccine development, and...

CD19 remains a hot target in immunotherapy, driving innovation across a range of diseases. This is evidenced by recent approvals...

The approval of Casgevy in the UK in December 2023, the first CRISPR gene editing drug, marked the era of...

Domain Antigens for Antibody Discovery & Screening The antibody drug development underwent rapid progress over the past decade, with almost...

Obesity is increasingly undermining human health. Obesity, a chronic metabolic disease, has significantly impacted the health and quality of life...

Rising Obesity Rates: A Global Threat Obesity, a chronic metabolic disease, has significantly impacted the health and quality of life...

What if a single cellular pathway could unlock new therapies for muscle regeneration, cancer, obesity, immune system regulation, and more?...

November 14, 2024 Base Therapeutics announced that its independently developed NK510 cell injection, the world's first base-edited universal NK cell...

With the first CRISPR gene-editing drug approved for over ten months now, what exciting developments are there in CRISPR drug...

Recent studies have shown that various drugs, including small molecules, opioids, and antibiotics, can activate MRGPRX2 (Mas-related G-protein coupled receptor...